Treatment of Secondary Immune Thrombocytopenia with Non-Hodgkin Lymphoma: A Case Report and Literature Review

Intern Med. 2021;60(10):1583-1588. doi: 10.2169/internalmedicine.5611-20. Epub 2021 May 15.

Abstract

Secondary immune thrombocytopenic purpura (ITP) with non-Hodgkin lymphoma (NHL) is a rare disease. Although some treatment regimens are available for primary ITP, the treatment strategy for secondary ITP remains unconfirmed. We herein report a 79-year-old man who was diagnosed with secondary ITP with mantle cell lymphoma. Although intravenous immunoglobulin (IVIG) has been considered an effective option for secondary ITP, similar to the treatment of primary ITP, our patient did not benefit from IVIG. A literature review including the current report revealed that IVIG was ineffective in all treated patients. Secondary ITP with NHL should be treated differently from primary ITP.

Keywords: chemotherapy; intravenous immunoglobulin; non-Hodgkin lymphoma; secondary immune thrombocytopenia.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Lymphoma, Non-Hodgkin* / complications
  • Lymphoma, Non-Hodgkin* / drug therapy
  • Male
  • Purpura, Thrombocytopenic, Idiopathic* / complications
  • Purpura, Thrombocytopenic, Idiopathic* / drug therapy
  • Thrombocytopenia*

Substances

  • Immunoglobulins, Intravenous